9 patients with cervical dystonia received increasing doses of 2.5 mg dronabinol or placebo for 3 weeks in a randomized order. The purpose of this study was to determine if dronabinol improved Toronto Western Hospital Spasmodic Torticollis Rating Scale, global impression scale, or visual analog pain scale scores compared to placebo, while maintaining a similar rate of adverse events. Results indicated that dronabinol had no significant effect on any primary or secondary outcome, but was associated with significantly more adverse effects. Only 7 of 9 patients completed the study.